Lobular Breast Carcinoma clinical trials

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Neratinib before surgery for HER2-mutated invasive lobular breast cancer

This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.

Lobular breast cancer with low hormone receptors

This study looks at a rare type of breast cancer called invasive lobular carcinoma that has low or no hormone receptors. The goal is to learn more about how this cancer behaves, which may help improve future treatments.

Finding the best tamoxifen dose to lower breast cancer risk

This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.

3-day radiation after breast-conserving surgery for certain breast cancers

This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.

Diet and inflammation score in women at high breast cancer risk

This study looks at whether a person’s diet that tends to cause more body inflammation is linked to future breast cancer risk. It may help researchers understand how eating patterns could affect risk in people already considered high-risk.

Radiation study for tumors that spread to soft tissue areas

This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.

Registry study for metastatic lobular breast cancer

This study collects health information from adults with invasive lobular breast cancer that has spread (metastatic) to help researchers understand factors linked to survival. Joining may help build better knowledge for future treatments and care planning.

PET/MRI scan for certain breast cancer types

This trial is studying if a special PET/MRI scan using a tracer called 18F FES can help doctors decide the best treatment for people with Luminal A or hormone-receptor-positive lobular breast cancer. The scan looks at estrogen receptors to see if your cancer might respond to hormone therapy.

PET scan to detect hormone therapy resistance in breast cancer

This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.

Low dose tamoxifen and omega-3 for breast cancer prevention

This study tests whether low-dose tamoxifen (a breast cancer prevention drug) or omega-3 supplements can lower breast cancer risk in postmenopausal women who are overweight and have a higher chance of getting the disease. The study lasts about 6 months and involves blood draws and a breast fluid test to see how the treatment affects breast cells.

Acolbifene vs low-dose tamoxifen to prevent breast cancer

This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.

New imaging test for invasive lobular breast cancer that has spread

This trial tests a new imaging agent, [68Ga]Ga DOTA-5G, to see if it can better detect invasive lobular breast cancer that has spread to other parts of the body. It involves a PET/CT scan and may help doctors understand the extent of your cancer.

Testing skipping breast surgery or radiation for top responders

This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.

Hormone therapy before surgery for lobular breast cancer

This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.

Tracking lobular breast cancer with a blood test

This study is testing a new blood test that looks for cancer DNA to track how lobular breast cancer responds to treatment. It is for people whose cancer has spread and who have not yet started treatment for the spread.

Hormone therapy with or without chemo for early breast cancer

This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.

68Ga-BED003 PET scan for certain cancers

This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.

Imaging scan to detect cancer-linked protein in several tumor types

This trial tests a new PET scan tracer that targets a protein found on certain cancer cells. It may help doctors better see and understand tumors in people with colorectal, gastric, pancreatic, lobular breast, or ovarian cancer.

Optimizing treatment for early HER2+ and triple-negative breast cancer

This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).

Surgery now versus radiation then delayed surgery for DCIS

This trial compares two approaches for ductal carcinoma in situ (DCIS): having surgery first versus getting radiation first and then having surgery later. It aims to see which plan controls DCIS better while affecting treatment timing and outcomes.

Compare a breast imaging scan with MRI in high-risk women

This study compares two ways of imaging the breast—molecular breast imaging (a scan that uses a small radioactive tracer) and standard breast MRI—to better find or rule out breast cancer. You may join if you are considered high risk and already have a breast MRI planned, and you can do both tests close together.

Pembrolizumab versus monitoring after triple-negative breast cancer response

This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.

White button mushroom supplement for inflammation in high-risk breast cancer

This trial tests whether a white button mushroom powder supplement can lower inflammation in postmenopausal women who have a high risk of breast cancer. If it helps, it could improve early prevention strategies for people at higher risk.